Prognostic modeling in pediatric acute liver failure

Vandana Jain, Anil Dhawan – 24 June 2016 – Liver transplantation (LT) is the only proven treatment for pediatric acute liver failure (PALF). However, over a period of time, spontaneous native liver survival is increasingly reported, making us wonder if we are overtransplanting children with acute liver failure (ALF). An effective prognostic model for PALF would help direct appropriate organ allocation. Only patients who would die would undergo LT, and those who would spontaneously recover would avoid unnecessary LT.

Projected outcomes of 6‐month delay in exception points versus an equivalent Model for End‐Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates

Sarah K. Alver, Douglas J. Lorenz, Michael R. Marvin, Guy N. Brock – 24 June 2016 – The United Network for Organ Sharing (UNOS) recently implemented a 6‐month delay before granting exception points to liver transplantation candidates with hepatocellular carcinoma (HCC) to address disparity in transplantation access between HCC and non‐HCC patients. An HCC‐specific scoring scheme, the Model for End‐Stage Liver Disease equivalent (MELDEQ), has also been developed.

Liver transplantation in Japan

Akihiko Soyama, Susumu Eguchi, Hiroto Egawa – 24 June 2016 – As of December 31, 2014, 7937 liver transplants (7673 living donor transplants and 264 deceased donor liver transplantations [DDLTs; 261 from heart‐beating donors and 3 from non–heart‐beating donors]) have been performed in 67 institutions in Japan. The revised Organ Transplant Law in Japan came into effect in July 2010, which allows organ procurement from brain‐dead individuals, including children, with family consent if the patient had not previously refused organ donation.

Liver transplantation significantly improves global functioning and cerebral processing

Vishwadeep Ahluwalia, James B. Wade, Melanie B. White, HoChong S. Gilles, Douglas M. Heuman, Michael Fuchs, Edith A. Gavis, Andrew Fagan, Felicia Tinsley, Dinesh Ganapathy, Leroy R. Thacker, Richard K. Sterling, R. Todd Stravitz, Puneet Puri, Arun J. Sanyal, Muhammad S. Siddiqui, Scott Matherly, Velimir Luketic, Joel Steinberg, F. Gerard Moeller, Jasmohan S. Bajaj – 24 June 2016 – The functional basis of cognitive and quality of life changes after liver transplant is unclear.

Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results

Markus Selzner, Nicolas Goldaracena, Juan Echeverri, Johan M. Kaths, Ivan Linares, Nazia Selzner, Cyril Serrick, Max Marquez, Gonzalo Sapisochin, Eberhard L. Renner, Mamatha Bhat, Ian D. McGilvray, Leslie Lilly, Paul D. Greig, Cynthia Tsien, Mark S. Cattral, Anand Ghanekar, David R. Grant – 24 June 2016 – The European trial investigating normothermic ex vivo liver perfusion (NEVLP) as a preservation technique for liver transplantation (LT) uses gelofusine, a non–US Food and Drug Administration–approved, bovine‐derived, gelatin‐based perfusion solution.

Subscribe to